ArticleClinical transplantation2024

Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant Rejection.

Lukas K van Vugt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.